Markets:

Overview

News

Currencies

International

Treasuries

Catalyst Pharmaceuticals, Inc. - Common Stock (NQ:CPRX)

24.39 -0.05 (-0.23%)

Streaming Delayed Price Updated: 10:02 AM EST, Feb 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Catalyst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Catalyst Pharmaceuticals Earnings Perspective: Return On Capital Employed ↗

December 15, 2022

Via Benzinga

Moderna Stock Shows Surprising Strength; Key Rating Upgraded ↗

December 14, 2022

See if Moderna stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day average.

Via Investor's Business Daily

Xenon Pharmaceuticals Stock Scores Rising Relative Strength Upgrade ↗

November 29, 2022

Xenon Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded to 92 Tuesday, up from 89 a day earlier.

Via Investor's Business Daily

Best Buy, Abercrombie & Fitch, Burlington Stores And Some Other Big Stocks Moving Higher On Tuesday ↗

November 22, 2022

U.S. stocks traded higher, with the Dow Jones gaining around 250 points on Tuesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Stock Market Rally Roars Higher On Cooling Inflation; Bitcoin, Meta, Tesla In Focus: Weekly Review ↗

November 11, 2022

Bitcoin hit a two-year low while Meta and Tesla were in focus.

Via Investor's Business Daily

Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?

November 11, 2022

Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel.

Via MarketBeat

Catalyst Pharma, The No. 1 IBD 50 Stock, Just Trounced Third-Quarter Expectations ↗

November 09, 2022

The company sells one drug, a treat for a rare muscle contraction condition.

Via Investor's Business Daily

Catalyst Pharmaceuticals Reports Record Third Quarter 2022 Financial Results and Provides a Corporate Update

November 09, 2022

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

Catalyst Pharmaceuticals Named BioFlorida 2022 Company of the Year

November 07, 2022

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

Can Mid-Cap Lantheus Continue its 2022 Outperformance?

October 28, 2022

Mid-cap Lantheus Holdings has been on a revenue growth spurt boosted by a new product called Pylarify, which helps detect prostate cancer in an imaging test.

Via MarketBeat

Topics ETFs Initial Public Offering

Catalyst Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 9, 2022

October 25, 2022

Conference Call and Webcast to be held on November 10, 2022, at 8:30 AM ET

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

These 3 Stocks Are Winning the Bear Market -- Here's How ↗

October 21, 2022

Picking the right markets to compete in makes surviving bear markets much more manageable for these companies.

Via The Motley Fool

Amgen Stock Shows Market Leadership With Jump To 90 RS Rating ↗

October 12, 2022

On Wednesday, Amgen stock hit a key technical milestone, with its Relative Strength Rating upgraded to 90, a rise from 78 the day before.

Via Investor's Business Daily

BioCryst Pharmaceuticals Stock Shows Rising Relative Strength ↗

October 10, 2022

On Monday, BioCryst Pharmaceuticals stock received an upgrade to its Relative Strength (RS) Rating, from 90 to 93.

Via Investor's Business Daily

Small-Cap Catalyst Pharma Is Among Market's Best Price Performers

October 04, 2022

Small-cap biotech Catalyst Pharmaceuticals has been outperforming the broader market amid earnings and revenue acceleration. It joined the S&P 600 last month.

Via MarketBeat

Topics Stocks

Catalyst Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for FIRDAPSE® Expanding Patient Population to Include Pediatric Patients

September 29, 2022

FIRDAPSE is Now a Treatment Option for All LEMS Patients 6 Years of Age and Older in the U.S.

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

Intercept Pharmaceutical Stock Sees RS Rating Rise To 91 ↗

September 27, 2022

Intercept Pharmaceutical shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Via Investor's Business Daily

Pain Therapeutics Stock Shows Rising Price Performance With Jump To 97 RS Rating ↗

September 23, 2022

Pain Therapeutics sees its Relative Strength Rating enter the elite 90-plus level.

Via Investor's Business Daily

Here Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This Year ↗

September 19, 2022

The biotech run off a June bottom is great — until you realize you could've netted more.

Via Investor's Business Daily

FedEx, UPS And Some Other Big Stocks Moving Lower In Today's Pre-Market Session ↗

September 16, 2022

U.S. stock futures traded lower this morning after recording losses in the previous session. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin ↗

September 15, 2022

The market is struggling, yet biotech stocks are acting like it's good times again. Here's why.

Via Investor's Business Daily

Akero Therapeutics Stock Joins Elite Club Of Stocks With RS Ratings Over 90 ↗

September 14, 2022

Akero Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 73 to 99.

Via Investor's Business Daily

Nikola, Bed Bath & Beyond And Some Other Big Stocks Moving Higher In Today's Pre-Market Session ↗

September 14, 2022

U.S. stock futures traded higher this morning ahead of the PPI data for August. Here are some big stocks recording gains in today’s pre-market trading session.

Via Benzinga

Why Catalyst Pharmaceuticals Shares Are Popping Off ↗

September 13, 2022

Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) shares are trading higher by 6.40% to $16.12 Tuesday after it was announced the company will join the S&P SmallCap 600.

Via Benzinga

Planet Labs, Core & Main And Some Other Big Stocks Moving Higher On Tuesday ↗

September 13, 2022

U.S. stocks traded lower, with the Dow Jones tumbling more than 800 points on Tuesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Why SeaChange International Is Trading Higher By Around 15%; Here Are 26 Stocks Moving Premarket ↗

September 13, 2022

Gainers Comera Life Sciences Holdings, Inc. (NASDAQ: CMRA) rose 41.7% to $2.72 in pre-market trading. Comera Life Sciences Form 4 filing showed multiple insiders purchased 122,600 shares at an average...

Via Benzinga

Why Amazon, Microsoft, Apple Shares Are Trading Lower, Here Are 50 Stocks Moving In Tuesday's Mid-Day Session ↗

September 13, 2022

Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 186% to $47.69 as the stock started trading on a 1-for-30 reverse split basis.

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

September 12, 2022

Gainers OpGen (NASDAQ:OPGN) shares rose 20.6% to $0.52 during Monday's after-market session. This security traded at a volume of 927.4K shares come close, making up 324.6% of its average volume over...

Via Benzinga

Sage Therapeutics Stock Scores Relative Strength Rating Upgrade ↗

September 09, 2022

On Friday, Sage Therapeutics stock received a positive adjustment to its Relative Strength (RS) Rating, from 86 to 91.

Via Investor's Business Daily

Amylyx Pharmaceuticals Stock Sees Relative Strength Rating Rise To 98 ↗

September 09, 2022

Amylyx Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating improve to 98, up from 83 the day before.

Via Investor's Business Daily

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.